Collectively, these data indicate that 2ME2, ATTM, and LCS-1 treatments decrease the total number of BLM- and CHEK2-deficient colonies, and also the sizes of 3D tumor spheres, suggesting each is a strong lead candidate therapeutic compound. Here, CHEK2 is linked to neoplasm.